Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | BAZ2B | Q9UIF8 | 5/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CREBBP | Q92793 | 11/20 | 0.39 |
| ▸ | BRD4 | O60885 | 7/20 | 0.39 |
| ▸ | EP300 | Q09472 | 5/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7983593 | 0.94 | RXFP1 (0.43) | RXFP1BAZ2BNOTUMMAPTLMNA | |
| SCHEMBL8152134 | 0.84 | RXFP1 (0.44) | RXFP1MAPTCA1CA2CA9 | |
| SCHEMBL30704842 | 0.84 | MKNK1 (0.44) | MAPT | |
| SCHEMBL29129830 | 0.84 | MKNK1 (0.44) | MAPT | |
| SCHEMBL6781079 | 0.81 | MAPT (0.42) | RXFP1MAPTCA1CA2CA9 | |
| SCHEMBL6781068 | 0.79 | RXFP1 (0.40) | RXFP1MEN1KMT2A | |
| SCHEMBL6785452 | 0.79 | RXFP1 (0.44) | RXFP1MAPTCA1CA2CA9 | |
| SCHEMBL6609264 | 0.78 | RXFP1 (0.49) | RXFP1MAPTCA1CA2CA9 | |
| SCHEMBL2952459 | 0.77 | RXFP1 (0.51) | RXFP1MAPTLMNACA1CA2 | |
| SCHEMBL30567319 | 0.77 | RXFP1 (0.51) | RXFP1MAPTCA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6197771-B1 | NERVOUS SYSTEM DISORDERS; ANTIISCHEMIC AGENTS; ALZHEIMER'SDISEASE; PARKINSON'S DISEASE; HUNTINGTON'S DISEASE | WARNER-LAMBERT COMPANY | 2001-03-06 | — | — | US | claimed |
| WO-1996028445-A1 | NOVEL GLUTAMATE (AMPA/KAINATE) RECEPTOR ANTAGONISTS: N-SUBSTITUTED FUSED AZACYCLOALKYLQUINOXALINEDIONES | WARNER-LAMBERT COMPANY (US) | 1996-09-19 | — | — | WO | claimed |
| US-6703391-B2 | THROMBOSIS, BRAIN DISORDERS, CARDIOVASCULAR DISORDERS, ALZHEIMER'S DISEASE, HUNTINGTON DISEASES | NEUROSEARCH A/S (DK) | 2004-03-09 | — | — | US | disclosed |
| US-20030114422-A1 | NOVEL QUINOXALINEDIONE DERIVATIVES, THEIR PREPARATION AND USE | NEUROSEARCH A/S (DK) | 2003-06-19 | — | — | US | disclosed |
| US-6197771-B1 | NERVOUS SYSTEM DISORDERS; ANTIISCHEMIC AGENTS; ALZHEIMER'SDISEASE; PARKINSON'S DISEASE; HUNTINGTON'S DISEASE | WARNER-LAMBERT COMPANY | 2001-03-06 | — | — | US | disclosed |
| US-6057313-A | TREATING CENTRAL NERVOUS SYSTEM DISORDERS | WARNER-LAMBERT COMPANY (US) | 2000-05-02 | — | — | US | disclosed |
| EP-0664807-B1 | QUINOXALINEDIONE DERIVATIVES AS EAA ANTAGONISTS | WARNER LAMBERT CO (US) | 1997-09-10 | — | — | EP | disclosed |
| WO-1996028445-A1 | NOVEL GLUTAMATE (AMPA/KAINATE) RECEPTOR ANTAGONISTS: N-SUBSTITUTED FUSED AZACYCLOALKYLQUINOXALINEDIONES | WARNER-LAMBERT COMPANY (US) | 1996-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114422-A1 | NOVEL QUINOXALINEDIONE DERIVATIVES, THEIR PREPARATION AND USE | CHRNA3, CHRNA7, CHRNB3 | RXFP1 228/4885BAZ2B 449/4885NOTUM 4300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.